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ABSTRACT
Hepatitis C virus is a RNA virus with very high speed replication. The clinical course of chronic hepatitis
C is frequently asymptomatic like other hepatitis viruses. Infection of hepatitis virus will activate the immune
system specifically as well as non-specifically. Mechanism of the immune system regulation is controlled by
tissues consisting of antibodies cells and cytokines. In the process, all of the immune systems integrate and
coordinate with the main agent-lymphocytes. Lymphocytes recognize antigens through the specific-surface
antigen receptors. Following exposure to viral chronic hepatitis virus, viremia takes place within 1-2 weeks.
In immuno-competent hosts, viremia will be preceded with the increase in transaminase enzyme and delayed
seroconversion of antibodies will occur.
Unlike other immunologic processes, these established antibodies are not protective in nature but serve
only as the sign that someone has been infected by hepatitis C. In most cases of hepatitis C virus infection,
this virus cannot be eradicated in the acute phase. Approximately 80-90% of acute infection progresses to
be chronic infection and in 50% of the cases, there is an increase in transaminase enzyme that reveals that
there is still liver cell damage. The degree of liver tissue damage in hepatitis depends on the number of virus
infecting and the activity of cytotoxic T cells.
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INTRODUCTION
Hepatitis C virus (HCV) is the main cause for chronic
liver disease, liver cirrhosis and hepatocellular carcinoma.
This disease has infected 170 million people worldwide
and around 2.7 million Americans. Approximately 40%
of the chronic liver disease in the United States is caused
by hepatitis C virus. In South-East Asia, the prevalence
of hepatitis C is 2.5-4.9% of people.
According to WHO, the prevalence of hepatitis C in
Indonesia is around 1-2.4% whereas in Jakarta,
according to Nurul Akbar (1994), it was 3.9% with even
distribution of gender and the most prevalent age was
> 50 years (11.4%). The survey conducted at Dr. Cipto
Mangunkusumo General National Hospital and one pri-
vate hospital in Jakarta in 1999 by Rino et al revealed
that there were increasing numbers of HCV cases by
74.9% due to drug abuse (positive anti HCV with the
mean age 21.2 + 4 years). It revealed that there was
shifting of onset age so that the risk for liver cirrhosis
and hepatoma increased.1,2,3
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ETIOLOGY
Clinical spectrum of hepatitis C
The clinical course of hepatitis C infection can be
seen in the above picture. The incubation period is around
7 weeks, namely around 2-30 weeks. Acute hepatitis C
is usually asymptomatic and 80-90% will progress to
chronicity. Around 20-30% of chronic HCV patients will
develop cirrhosis within 10-20 years and 5-10% of them
will suffer from late-stage liver disease with the risk for
hepatoma around 1-4% annually from those with
cirrhosis.
The general symptoms are not typical such as
lethargy, anorexia, nausea, upper quadrant abdominal
pain, brownish urine and itch can appear and will
resolve or disappear while the progression of the
disease goes on to be chronic. Generally, acute HCV
patients will have increasing levels of aminotransferase
enzyme and only 25-30% of them have normal levels.
This increase will fluctuate 1.5 up to 10 times the normal
level and intermittently can decline approaching the
normal value.
Several trials have proven that around 1/3 of chronic
HCV patients have normal ALT enzyme levels.
Previously, these patients were regarded as healthy   virus
carriers, but since the biopsy results have proven that
there is change in the histopathological findings, this
opinion has been out of date. Now, these patients are
regarded as subclinical HCV patients.
Characteristics of hepatitis C virus
Hepatitis C virus is a RNA virus with positive ge-
nome that is derived from the family of flaviviridae. The
diameter is around 30-60 nm with the length 9.4 kb or
9,413 nucleotides and possesses an open reading frame
(ORF). This virus managed to be identified in 1987 and
is postulated to account for 80-90% of the cause of viral
hepatitis infection-non A, non B. Replication of this
virus occurs through a RNA-dependant RNA
polymerase. The speed of the virus replication is very
high, ranging from 1010 - 1012 copies of virus daily.
Heterogenicity occurs due to mutation during
replication. Consequently, HCV infected patients can
harbor hepatitis C virus with different nucleotide matrix.
This enables the virus to avoid the host’s immunologic
response in the efforts to survive. Heterogenicity also
has a role in influencing the course of the disease,
response to anti-viral agents and difficulty in inventing
a vaccine against HCV.
Right now, 6 genotypes of HCV have been identified
with 11 subtypes. Genotype 1 is abundant in North
America (60%) followed by genotypes 2 and 3.
Genotypes 4 are frequently found in Egypt, whereas
genotype 5 is found in North Africa and 6 in South-East
Asia. These genotypes are correlated with the therapy
response but not correlated with the severity of the
disease and levels of alanine aminotransferase enzyme.
The clinical course of chronic hepatitis C is frequently
asymptomatic like other hepatitis viruses. The most
often abnormality found is the increase in ALT levels in
some patients, but the level is still normal in some other
patients.
Since May 1990, there has been an antibody test
against HCV with the method Enzyme-Linked
Immunoassay (ELISA). The sensitivity of this test is very
high; almost up to 95% in high-risk population and 25%
in     low-risk population. False positive is often found in
blood donors so that recombinant immunoblast assay
(RIBA) has been developed lately. It can be used to
confirm the positive result of ELISA test in low-risk
population. However, with the development of RNA
detection method, either qualitatively or quantitatively,
this test is seldom used now.
Qualitative RNA test is the most sensitive test and
can defect the number of virus eventhough it is in very
low quantities. (< 100 copies of HCV RNA/IU). This
examination is very useful in determining the presence
of HCV virus in immunocompromised patients and the
presence of persistent infection in patients with positive
antibodies.
Immun response to hepatitis virus
Infection of hepatitis virus, like other viral infections,
will activate the immune system specifically as well as
non-specifically. The non-specific immune system is an
immune system that works directly without any
exposure to the previous antigen and is frequently
referred to as natural immune system. This immune
system is the first defense that consists of physical/
mechanical defense, namely skin, mucosa, cilia, cough/
sneeze,  physiological defense and biochemistry (gastric
pH, lactopherine, lisozim) cellular non-specific defense
occurs through the production of interferon (IFN) and
activation of natural killer cells (NK) whereas the
specific defense consists of humoral and cellular immune
responses.1-4
Mechanism of the immune system regulation is
controlled by tissues consisting of antibodies cells and
cytokines. In the process, all of the immune systems
integrate and coordinate with the main agent-
lymphocytes. Lymphocytes recognize antigens through
the specific-surface antigen receptors.
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Virus serves as an antigen that causes local
accumulation of mononuclear cells that exit from the blood
vessels. This occurs through adhesion based on the
signal of the endothelial cells and target cells. The
cellular factors and cytokines involved are:
• CD4+ CD8+
• ICAM-1 (Intercellular adhesion molecule 1)
• Cytokines : interleukin, TNF, interferon
Humoral immune response
Following exposure to HCV virus, viremia takes place
within 1-2 weeks. In immunocompetent hosts, viremia
will be proceeded with the increase in transaminase
enzyme and delayed seroconversion of antibodies will
occur. Unlike other immunologic processes, these
established antibodies are not protective in nature but
serve only as the sign that someone has been infected
by hepatitis C.
In most hepatitis C virus-infected patients, the host’s
immune system fails to eliminate the virus in the acute
phase. This condition causes almost 80% of HCV
infection to progress to chronicity.
If viral infection occurs, NK cells will recognize the
infectious cells non-specifically and destroy them. These
infected cells will secrete interferon (alpha and beta)
that will cause repression of the replication process of
virus. If this process fails, cytotoxic T cell lymphocytes
(CTL), together with neutralizing antibodies will take over
the role in destroying these infected cells.
Neutralizing antibodies will bind to particles of
specific virus that exist in the body’s fluid and eliminate
them. However, some trials have proven that the
neutralizing antibody response is very strain-specific in
nature. In addition to that, the quasispecies nature of this
virus can cause the emergence of other strains when
the predominant strain is repressed by the immune
system. This nature will create an obstacle for inventing
a vaccine against hepatitis C infection.
Several trials have mentioned that antibody response
to the hypervariable protein E2 from the HCV viral
structure was correlated with the incidence of
resolution from HCV infection.1
Cellular and cytokine immune response
Cytotoxic T cells (Cytotoxic T Cell Lymphocyte/CTL)
and neutralizing antibodies are directly involved in the
eradication process of virus from the body’s fluid and
kill virus that infects cells. Antibody production and
activation as well as proliferation of cytotoxic T cells
are controlled by T-helper cells. T-cells are activated on
identification of viral antigens that are presented by APC
cells. Identification of cells infected with this virus by
T cells, CD4+ or CD8+ requires presentation of peptide
virus through major histocompatibility complex molecules
(MHC)I and II.3
CTL will recognize viral antigens expressed onto the
surface of the infected cells by antigen presenting cell
(APC) and then attack those cells in the effort to
eliminate the virus.
Cytokines are peptide molecules secreted by cells
and function as a communication tool with other cells.
Cytokines produced by lymphocyte cells are referred to
as lymphokine. Cytokines that function as the regulators
for cell movement toward a lesion (chemotaksis) are
called chemonin. Interleukin is a cytokine that serves to
send messages among leucocytes. Surface molecules
are the sign of cell identity that is named after the
function. T lymphocyte cells have 2 kinds of surface
molecules that are named CD4+ and CD8+. CD4+ cells
generally bear the nature as T helpers and CD8+ as
cytotoxic cells.
Response of CD8+ lymphocyte T cells
Based on the cumulative data, it can be seen that
response of specific antigen CD8++, cytotoxic T
lymphocytes (CTL) in hepatitis C will persist
permanently in patients with chronic hepatitis C that has
undergone mutation. Some trials have shown that CTI
specific HCV can generate in liver cells or in the
peripheral blood. Quantitative and qualitative analysis of
the cellular immune response in hepatitis C has revealed
that T-specific CD8+ cells exist in the peripheral blood
cells of patients with the number relatively lower than
that in the intrahepatic.
Some studies that investigated the response of CTL,
specific HCV correlated with the number of virus
revealed that there was correlation between
the numbers of virus with the response activity of CTL
specific. Nelson et al obtained that in patients with CTL
specific activity, the high HCV had the concentrations
of RNA HCV below 0.5-1 log. This revealed that CTL
specific activity was essential in the elimination process
of virus.
Response of MHC II lymphocyte T-cell
CD4+ constituens an induction center to respond to
antivirus because it can increase the antibody response
by producing B cells and activities the cell activity of
CD8+. The latest development in the meaning about the
cellular immune response regulation toward infection
agents is by identifying 2 subpopulations of lymphocyte
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T helper T cells (CD4+) based on the cytokine produced
namely T-helper 1 (Th1) and T-helper (Th2) as well as
Th0 that’s not active.1
The cells will activitate the cellular immune response
and cytotoxic T cell response. If activated, Th1 cells will
produce IL-2 and IFNγ to precipitate the activation and
proliferation of cycotoxic T cells, TNFα and NK cells.
Th2 cells have more roles in the humoral immunity.
These cells will produce IL-4, IL-5, IL-6 and IL-10 that
will stimulate differentiation of b cells to be antibody
plasma cells (APC) as well as to proliferate. APC also
produces IL-12 when activated by T cells. These
cytokines serve as Th1 cells, T cells and NK cells that
work to eliminate and inhibit the replication of virus.4
In hepatitis virus A and B, the mechanism of the
cellular immune response is like the forementioned
mechanism. However, in most cases of hepatitis C virus
and some cases of hepatitis B virus, the virus cannot be
eradicated in the acute phase. Consequently, a variety
of cell damage will keep on depending as the ratio
between the numbers of virus as antigens that infect
cells with the specific activation of cytotoxic T cells.
Mechanism of hepatocellular injury in hepatitis
virus
Cytotoxic T cells are the main agents in the process
of liver cell damage following the infection of hepatitis
virus. These cells will be activated if they recognize the
cells infected by virus and will release a protein called
perforin. This perforin will perforate the membrane of
the target cell by injecting a proteolitic enzyme produced
that is called granzim. Through this mechanism, the cells
are killed.
Activated cytotoxic T-cells will increase the
expression of Fas ligand (FAS) and TNFα, if these cells
are sensitive to Fas ligand or TNFα, activated cytotoxic
T cells will damage the cells, either those that are
infected or those that are not infected. This process
occurs through the release of apoptosis signals
mediated by Fas ligand antigen and TNFα.
Cytotoxicity of Fas antigen and Fas ligand system or
TNFa is lower than that of perforin. It occurs because
this system attacks most uninfected cells, but those cells
have obtained sensitivity (immune) because they have
undergone damage. The damage occurs through a
mechanism that is correlated with the inflammatory
process, whereas perforin only damages the virus-
infected cells. The molecular mechanism that causes
damage in these virus-infected cells has been proven
through trials by using cytotoxic T cell clones that are
specific for Hepatitis C4 virus.
Mechanism of liver cell damage in infection of
hepatitis virus
Lymphocyte cytotoxic T cells that have recognized
the liver cells infected by virus will be activated and
proliferate under the stimulation of cytokines, such as
IL-2 and IFNg that are produced and activated by T
helper cells. As explained above, perforin is regarded as
an important role in the hepatocellular injury process.
Production of Fas ligans and TNFa increases when the
cytotoxic T cells are activated. When the increase in the
expression of Fas receptors and TNF occurs in the
process of hepatitis, liver cells become sensitive to Fas
and TNFa receptors even through in fact, it has under-
gone slight sensitivity in the normal condition. Based on
this, these two systems are considered having a correla-
tion with the damage of cells in hepatitis virus infection.
In a trial a patients with chronic hepatitis C virus,
expression of Fas antigen would increase at the site of
the severe inflammation process. In that trial, the
involvement of perforin. Fas and TNFα was also
reported in the severe hepatocellular damage in hepati-
tis experimental models. INFγ secreted by cytotoxic T
cells and activated by T helpers can activate
macrophages. This macrophage activation will secrete
TNFα so that mobilization of inflammatory cells, like
neutrophils, occurs through the activation of endothelial
cells and fibroblasts. Activation of these inflammatory
cells will cause virus hepatitis infection to be more
aggressive.
The severity of hepatitis varies depending on the
potential replication of virus, antigenicity of virus and
host’s immune response cells. Potential replication and
anti-genicity of hepatitis virus A and B are very high
that can cause hepatitis to be fulminant. In hepatitis C,
virus does not replicate fast and the antigenicity is not
too high so that it is seldom fulminant in the HCV
infection.
In HBV and HCV infection, the viral infection that
will persist will regress the host’s immune response.
Th2
Th1
Th0 IFN , IL-2, TNFγ α
IL-4, IL-5, IL-10
Immunities cell mediated
Humoral immune
Antivirus,
klirens pathogen
intracellular
Proinflammation
Anti inflammation
Antibody
Figure 1.  Identifyng CD4+ based on cytokine produced1
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Depletion, tolerance and participation of T suppressor
cells are postulated in the suppression mechanism of
immune cells even though the exact mechanism has not
been clear yet. If persistent viral infection occurs
concomitantly with the cellular immune response that is
not adequate to eradicate the virus, chronic liver
damage will occur even through it is not as severe as the
damage in acute hepatitis.
Despite the fact, that several mechanisms that have
the role in the hepatocellular injury and liver cell
damage, have been explained, but how hepatitis can
occur in healthy carriers and the suppression
mechanism of the cellular immune system in chronic
hepatitis has still not been elucidated.1,4
Immunopathogenesis of hepatitis C
a. Host’s immune/response in the infection of
Hepatitis C virus
In 1994 Gonzales stated that liver cell damage in the
HCV infection was postulated not to be caused by
the cytopathic nature of the virus, but by the
interaction of the virus with the host’s immune
response. The mechanism of hepatocellular damage
in hepatitis C has not been clearly understood, there
is interaction of factors that influence the immune
response and it is very individual those factors
include the virus factor per se such as the cytopathic
effect, the ability to replicate and heterogenicity. The
host factor includes the specific and non-specific
immune systems as well as production of local and
systemic cytokines. The environment factor like
immunosuppression and alcoholism also has the role
in determining the progressivity of disease.
The host’s immune response in the infection of
hepatitis C virus will involve the non-specific and
specific immune systems. The specific immune has
cellular components (T lymphocyte and humoral B
lymphocyte or immunoglobulin). The cellular
component consists of leucocytes, mast cells,
macrophagues, T cells (Th0, h1, h2) and B cells.
The cellular immune response is activated by acti-
vation of CD4+ and CD8+ cells.
According to Alvarado (1999) based on his trial, it
was proven that the immune response had a role in
the pathogenesis of liver disease in (HCV), but the
immune response of B cells and TCD4+ cells and
CD8+ that are not effective cannot prevent the
course of the disease so that it can cause chronic
infection.
Up to now, the mechanism of immunity has not been
able to be explained. The role of lymphocyte T cells,
in this context, CD4+ and CD8 are still being
investigated. Some trials have mentioned that CD4+
lymphocyte T cells had more roles in the elimination
process of hepatitis C virus infection compared with
CD8+ in acute infection. In addition to that,
heterogenicity of HCV also causes antibodies to
neutralize the immune system that is not capable of
protecting the body against immunological response.
Chang et al in his trial on chimpanzees obtained that
quantitatively the level of CD8+ did not adequately
cause infection to be persistent, but the role of CD8+
T cell response in human beings has not been well
understood. Like in other virus infections, CD4+ T
cell and CD8+ cell response are correlated. CD4 is
required to activate CD8+ even though the
correlation between the cellular immune response
and the clinical condition or virology in hepatitis has
not been clear yet.
Immune response in the infection of hepatitis virus
is initiated when infection of liver cells occurs that
stimulates the production of interferon a and b. Both
of them will inhibit the replication of virus. If the
infection cannot be control, the role to eliminate this
virus will be taken over by neutralizing antibodies
and cytotoxic T cells. These antibodies will
neutralize virus in the body fluid and cytotoxic T cells
will recognize, express and destroy the virus.3
In most cases of hepatitis C virus infection, this
virus cannot be eradicated in the acute phase.
Approximately 80-90% of acute infection progresses
to be chronic infection and in 50% of the cases, there
is an increase in transaminase enzyme that reveals
that there is still liver cell damage. The degree of
liver tissue damage in hepatitis depends on the
number of virus infecting and the activity of
cytotoxic T cells.1,2,4
In acute HCV infection, the humoral response has a
role with the formation of antibodies against virus.
However the role of antibody toward infection has
still been not known.
b. The role of cellular response and cytokines in
HCV infection
The cellular immune response is produced by CD4+
and CD8+ against the HCV antigens. Cytokines
released by CD4+ and CD8+ directly inhibit
replication of virus. Compared with hepatitis B,
hepatitis C is resistant to the repression effect of
cytokines so that the role of other cytokines that
cause liver cell damage becomes clear.1,2
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As explained before, Th1 cells will produce
interleukin-2 cytokine (IL-2) and interferon gamma
(IFNg). These cytokines are required to increase
the host’s cellular immune response in killing the  virus.
Th2 cells produce IL-4, IL-5 and IL-10 that
function to augment the production of antibodies for
humoral immunity, but also inhibit the Th1 response,
especially interferon. The imbalance between
cytokine production of Th1 and Th2 has the effect
on the progression of disease or irreversible
infection. In hepatitis C, the cellular immune response
is dominant but the activation patterns are toward
activation of Th2. This will cause the elimination
process of virus to be ineffective.1,4
The occurrence of chronic HCV is caused by other
mechanisms such as ‘escaped mutant’ due to the
high speed of mutation besides the imbalance of
cytokines. Patients that recover from acute HCV
infection and do not become chronic have strong Th1
response and weak Th2 response. Conversely,
patients whose infection becomes chronic have a
lack of Th1 response and strong Th2 response.1,2,4-11
Tsai et al also obtained a correlation between the
Th1 response with recovery of HCV infection and
Th2 response revealed a going process toward
chronic hepatitis.
CD4+ T cell response to viral protein is important to
protect the host’s cells. CD4+ T cells can control
and protect liver cells from hepatocellular damage.
Generally, trials are aimed at observing the
proli-feration of CD4+ + cells from the peripheral
blood compared with the intrahepatic.
Diepolder et al obtained a correlation between
clearances of HCV NS3 virus with the specific T
helper cellular immune response in trials consisting
of 14 patients with acute Hepatitis C Virus.
According to Minutello et al, in patients with active
chronic liver, the proliferation response to CD4 was
higher than in carriers so that it was postulated that
there was correlation between the activities of the
disease with CD4+
The role of immune system in the treatment
Principally, the objective of treatment for viral
infection hepatitis is to eliminate virus, prevent
progressivity as well as to reduce the risk for cirrhosis
and hepatoma. The standard treatment with antiviral
agents and hepatoprotectors has been believed to be able
to prolong the life expectancy of HCV patients.
The role of interferon in viral infection is through, the
following process:
• To inhibit replication of virus by inhibiting RNA
transcription and replication of DNA
• To increase the expression of MHC 1 molecules
(CD8+) to recognize viral antigens
• To stimulate the development of Th1
• To increase the activity of NK cells and
macrophagues
• To inhibit the penetration of virus into the cells
A trial conducted in Taiwan proved that ribavirin
could increase the cellular immune response in HCV
infection and was correlated with the increase in the
secretion of IL-12. The sophisticated therapy Th which
has been developed is the usage of pegylated interferon.
This therapy is regarded as a beneficial one based on
the kinetic HCV RNA response that reincreases after
24 hours following the treatment by standard interferon.
Pegylated has longer bioavailability in the body because
it is gradually absorbed and gradually excreted and is
postulated to be able to reduce the immunity reaction of
HCV virus.
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